跳至主要内容
临床试验/NCT01913093
NCT01913093已完成不适用

N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors

The Hospital for Sick Children1 个研究点 分布在 1 个国家目标入组 204 人开始时间: 2013年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
204
试验地点
1
主要终点
DIVERGET

研究概览

简要总结

To find possible therapeutic targets to help prevent long-term brain and behavioural side effects in survivors of childhood leukemia that may have been caused by chemotherapy (Treatment-Related late Adverse Neuro-Cognitive Effects: TRANCE). The study hypothesis is that genetic variations of the elements in the folate-related cycles and methotrexate disposition networks are associated with the deficit phenotype (TRANCE) of childhood leukemia survivors.

详细描述

Hypothesis Genetic variants of the elements in the folate-related cycles and methotrexate disposition networks are associated with the TRANCE phenotype of childhood leukemia survivors.

Objectives

  1. To identify TRANCE phenotypes of the childhood leukemia survivors.
  2. To characterize the folate and vitamin B12 levels of these children
  3. To identify DNA methylation patterns associated with TRANCE trait in the leukemia survivors
  4. To identify SNPs associated with the TRANCE trait in the leukemia survivors.
  5. To identify the "deficit genotype" associated only with the TRANCE leukemia survivors, but not with general population children who show developmental phenotypes similar to TRANCE: TRANCE-unique deficit variant
  6. To replicate the association between the TRANCE-unique deficit variants and the TRANCE trait in a population of childhood leukemia survivors.
  7. To evaluate the importance of rare genetic variants in the TRANCE trait in the leukemia survivors.

Study design: A case-control study of leukemia survivors

Analyses

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
8 Years 至 20 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Past diagnosis of acute lymphoblastic leukemia
  • 8 years : 0 months - 20 years : 11 months old at the time of their study visit
  • At least 2 years : 0 months from the last treatment for acute lymphoblastic leukemia at the time of their study visit
  • Continuous complete remission and undergone no bone marrow transplantation or cranial radiation therapy
  • Fluent in English (a subject and one parent) for test completion
  • Signed informed consent

排除标准

  • Inability to complete the phenotyping tests
  • Down Syndrome diagnosis

结局指标

主要结局

DIVERGET

时间窗: Within 6 months from the enrolment

This is a short battery of tests that has been shown to be predictive of both global and academic impairment in survivors of childhood cancer. All neuro-cognitive tests are done on a same day.

Stop Signal Task (SST)

时间窗: Within 6 months from the enrolment

Response inhibition, disturbed by behavioral inattention, will be characterized using our task-based computer program, the Stop Signal Task (SST). All neuro-cognitive tests are done on a same day.

CONNERS 3

时间窗: Within 6 months from the enrolment

To characterize behavioural aspects, we will administer the standard measure based on parent report. All neuro-cognitive tests are done on a same day.

Pathway-based gene variant status

时间窗: Within 3 months from the end of enrolment

In the hypothesis-driven genome-wide approach, we will focus on the candidate pathways/regions including (but not limited to): a) Folate/methionine cycle genes and transporters; b) drug metabolizing enzymes and transporters (including families of CYP, SLC and ABC transporters); c) epigenetic modifying factors; and d) neuro-regeneration and tissue repair.

次要结局

  • WIAT-III numerical operations and math fluency composite score(Within 6 months from the enrolment)
  • Serum vitamin B12(Within 6 months from the enrolment)
  • Folate, vitamin B12 and iron intake(Within 6 months from the enrolment)
  • Folate status(Within 6 months from the enrolment)
  • WISC-IV(Within 6 months from the enrolment)
  • Brief Rating Inventory of Executive Function (BRIEF)(Within 6 months from the enrolment)
  • N-Back Task(Within 6 months from the enrolment)
  • Iron status(Within 6 months from the enrolment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shinya Ito

Division Head, Clinical Pharmacology and Toxicology

The Hospital for Sick Children

研究点 (1)

Loading locations...

相似试验